GlassScriptPhysician profile
Robert H Mckinney
NPI 1861485179
$3,634.05
in general payments reported to CMS, 2019-2025
29 companies · $407 in 2025
The $407 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $296 · 2020: $603 · 2021: $554 · 2022: $833 · 2023: $488 · 2024: $453 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,348.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $429.22 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $397.60 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Daiichi Sankyo INC. | $313.01 | 2019-2022 | |
| Amgen INC. | $298.26 | 2020-2025 | Otezla, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $267.93 | 2022-2024 | |
| Abbvie INC. | $246.39 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $172.82 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $168.18 | 2020-2023 | Xifaxan |
| Pfizer INC. | $159.39 | 2019-2023 | |
| Lilly USA, LLC | $151.00 | 2019-2024 | Zepbound |
| Abbott Laboratories | $138.68 | 2022-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $138.02 | 2019-2020 | |
| Astellas Pharma US INC | $131.53 | 2024-2025 | Veozah |
| Merck Sharp & Dohme LLC | $127.03 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Pharmacosmos Therapeutics INC. | $80.76 | 2020-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $67.20 | 2025 | Caplyta |
| Exact Sciences Corporation | $60.79 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $54.39 | 2021 | |
| Hologic Sales and Service, LLC | $42.33 | 2023 | Myosure Tissue Removal Device, Coolseal Generator |
| Phathom Pharmaceuticals, INC. | $42.04 | 2024 | Voquezna |
| Mckesson Medical-Surgical, INC. | $20.21 | 2025 | |
| Supernus Pharmaceuticals, INC. | $20.06 | 2024 | Qelbree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.51 | 2020 | |
| Radius Health, INC. | $17.19 | 2024 | Tymlos |
| Biogen, INC. | $15.90 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.50 | 2021 | |
| Mylan Specialty L.P. | $15.50 | 2023 | Yupelri |
| Shield Therapeutics INC | $13.08 | 2024 | |
| Novartis Pharmaceuticals Corporation | $12.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mckinney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.